Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04622774 | First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 56 | ImmunoGen, Inc.INDUSTRY | 3 | Jan 15, 2025 | clinicaltrials |
| NCT01902173 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02323880 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas |
| completed |
| Phase 1 |
| 59 |
| Children's Oncology GroupNETWORK |
| 1 |
| Jan 14, 2025 |
| clinicaltrials |
| NCT02975882 | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 33 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06012708 | Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 | completed | Phase 1 | 12 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04727554 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | AmgenINDUSTRY | 10 | Jan 6, 2025 | clinicaltrials |
| NCT05169697 | A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 6 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT05176509 | A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors | completed | Phase 1 | 5 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06228846 | An Phase I Study of YY001 in Patients with Advanced Solid Tumors | completed | Phase 1 | 16 | Shanghai Yuyao Biotech Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03950570 | ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 58 | Orinove, Inc.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT02610361 | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors | completed | Phase 1 | 131 | BeiGeneINDUSTRY | 2 | Dec 27, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT05279690 | Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors | completed | Phase 1 | 16 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05394818 | The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors | completed | Phase 1 | 19 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05414136 | Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 | completed | Phase 1 | 37 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT02746081 | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | completed | Phase 1 | 81 | BayerINDUSTRY | 4 | Dec 18, 2024 | clinicaltrials |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | completed | Phase 1 | 72 | Merus B.V.INDUSTRY | 4 | Dec 11, 2024 | clinicaltrials |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | completed | Phase 1 / Phase 2 | 40 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03030417 | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04672434 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 48 | Symphogen A/SINDUSTRY | 2 | Dec 9, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT05018273 | Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors | completed | Phase 1 | 26 | Nykode Therapeutics ASAINDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05246111 | Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) | completed | Phase 1 | 6 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT00909025 | Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer | completed | Phase 1 | 15 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT05357820 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | completed | Phase 1 | 56 | Nuvation Bio Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05357911 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | completed | Phase 1 | 16 | Nuvation Bio Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00514007 | Study of Continuous OSI-906 Dosing | completed | Phase 1 | 95 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00514306 | Study of Intermittent OSI-906 Dosing | completed | Phase 1 | 79 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00739453 | A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) | completed | Phase 1 | 95 | Astellas Pharma IncINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT03027128 | QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 6 | ImmunityBio, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05990920 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | completed | Phase 1 | 6 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02561455 | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | completed | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03834662 | A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies | completed | Phase 1 | 19 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 19, 2024 | clinicaltrials |
| NCT02699515 | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 114 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT03945253 | Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Astellas Pharma IncINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04855929 | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.(ANV419-001) | completed | Phase 1 | 55 | Anaveon AGINDUSTRY | 3 | Nov 8, 2024 | clinicaltrials |
| NCT01529684 | A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body | completed | Phase 1 | 5 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02456883 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT03666143 | A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 216 | BeiGeneINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT01359982 | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects(DINAMIC) | completed | Phase 1 | 26 | EpicentRx, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03457532 | A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors | completed | Phase 1 | 177 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT02038673 | An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | completed | Phase 1 | 86 | Astellas Pharma IncINDUSTRY | 4 | Oct 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 15, 2025source: clinicaltrials